About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

379206 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/23/2021.
This website is for US healthcare professionals
close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Our Science

Pipeline Molecules

We invest significant resources into creating disease-altering therapies for cancers. Hundreds of clinical studies around the world use our innovative treatment.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

Filter by:

Flip

azacitidine

( DNA Methyltransferase Inhibitor )

Learn More View clinical trials
with this compound
Phase

azacitidine

DNA Methyltransferase Inhibitor

Azacitidine is a cytidine nucleoside analogue?that is incorporated into newly synthesized DNA as well as RNA.

Learn More

Flip

bb21217

( Anti-BCMA CAR T Cells )

View clinical trials
with this compound
Phase 2

bb21217

Anti-BCMA CAR T Cells

Flip

Phase 2

CC-90001

JNK Inhibitor

Flip

CC-90009

( Cereblon/E3 Ligase Modulator )

Learn More View clinical trials
with this compound
Phase 1

CC-90009

Cereblon/E3 Ligase Modulator

Learn More

Flip

Phase 1

CC-90010

BET Inhibitor

Flip

CC-90011

( LSD1 Inhibitor )

View clinical trials
with this compound
Phase 1

CC-90011

LSD1 Inhibitor

Flip

CC-92480

( Cereblon/E3 Ligase Modulator )

Learn More View clinical trials
with this compound
Phase 1

CC-92480

Cereblon/E3 Ligase Modulator

Learn More

Flip

CC-93269

( Anti-BCMA T-Cell Engager )

Learn More View clinical trials
with this compound
Phase 1

CC-93269

Anti-BCMA T-Cell Engager

CC-93269 is an investigational, humanized IgG1-based 2+1 T-cell engager (TCE) designed to bind to B-cell maturation antigen (BCMA).

Learn More

Flip

CC-94676

( Androgen Receptor Ligand-Directed )

View clinical trials
with this compound
Phase

CC-94676

Androgen Receptor Ligand-Directed

Flip

CC-95251

( Anti-SIRP? Antibody )

View clinical trials
with this compound
Phase 1

CC-95251

Anti-SIRP? Antibody

Flip

Phase 1

CC-95775

BET Inhibitor

Flip

Phase

CC-97540

CD19 NEX T

Flip

Phase

CC-98633

BCMA NEX T

Flip

CC-99282

( Cereblon/E3 Ligase Modulator )

Learn More View clinical trials
with this compound
Phase 1

CC-99282

Cereblon/E3 Ligase Modulator

Learn More

Flip

CC-99712

( Anti-BCMA Antibody Drug Conjugate )

View clinical trials
with this compound
Phase 1

CC-99712

Anti-BCMA Antibody Drug Conjugate

Flip

cendakimab

( Anti-IL13 Antibody )

View clinical trials
with this compound
Phase 2

cendakimab

Anti-IL13 Antibody

Flip

Phase 2, Phase 3

enasidenib

IDH2 Inhibitor

Enasidenib is an oral, reversible, selective inhibitor of mutated isocitrate dehydrogenase (IDH) 2.

Learn More

Flip

Phase 3

fedratinib

JAK2 Inhibitor

Fedratinib is an investigational, selective, small-molecule, ATP-competitive inhibitor of Janus kinase 2 (JAK2).

Learn More

Flip

GEM333

( CD3xCD33 Bispecific [GEMoaB] )

View clinical trials
with this compound
Phase 1

GEM333

CD3xCD33 Bispecific [GEMoaB]

Flip

GEM3PSCA

( CD3xPSCA Bispecific [GEMoaB] )

View clinical trials
with this compound
Phase 1

GEM3PSCA

CD3xPSCA Bispecific [GEMoaB]

Flip

iberdomide (CC-220)

( CELMoD? agent )

Learn More View clinical trials
with this compound
Phase 1, Phase 2

iberdomide (CC-220)

CELMoD? agent

Iberdomide is a CELMoD agent.

Learn More

Flip

idecabtagene vicleucel (ide-cel; bb2121)

( Anti-BCMA CAR T Cells )

Learn More View clinical trials
with this compound
Phase 2, Phase 3

idecabtagene vicleucel (ide-cel; bb2121)

Anti-BCMA CAR T Cells

Idecabtagene vicleucel (Ide-cel; bb2121) is an investigational chimeric antigen receptor (CAR) T cell therapy targeting B-cell maturation agent.

Learn More

Flip

Phase 3, Phase Post Approval Research

lenalidomide

IMiD? Agent

Lenalidomide is an oral, small-molecule immunomodulatory agent.

Learn More

Flip

lisocabtagene maraleucel (liso-cel; JCAR017)

( Anti-CD19 CAR T Cells )

Learn More View clinical trials
with this compound
Phase 2, Phase 3

lisocabtagene maraleucel (liso-cel; JCAR017)

Anti-CD19 CAR T Cells

Lisocabtagene maraleucel (liso-cel;JCAR017) is an investigational chimeric antigen receptor (CAR) T cell therapy designed to target CD19.

Learn More
Phase 2, Phase 3

luspatercept-aamt

Luspatercept-aamt (ACE-536) is a soluble fusion protein hypothesized to act as an erythroid maturation agent.

Learn More

Flip

marizomib

( Proteasome Inhibitor )

Learn More View clinical trials
with this compound
Phase 3

marizomib

Proteasome Inhibitor

Marizomib is a proteasome inhibitor derived from a novel marine-obligate actinomycete.

Learn More

Flip

Phase 1

motolimod

TLR8 Agonist

Flip

nab-paclitaxel

( Albumin-Bound Microtubule Inhibitor )

Learn More View clinical trials
with this compound
Phase 3, Phase Post Approval Research

nab-paclitaxel

Albumin-Bound Microtubule Inhibitor

nab-Paclitaxel is a taxane that uses albumin to deliver paclitaxel.

Learn More

Flip

Oral HMA (CC-486)

( DNA Methyltransferase Inhibitor )

Learn More View clinical trials
with this compound
Phase 1, Phase 2, Phase 3

Oral HMA (CC-486)

DNA Methyltransferase Inhibitor

The epigenetic modifier CC-486 (an oral formulation of azacitidine)?is a cytidine nucleoside analogue.

Learn More

Flip

orvacabtagene autoleucel (orva-cel; JCARH125)

( Anti-BCMA CAR T Cells )

Learn More View clinical trials
with this compound
Phase 1

orvacabtagene autoleucel (orva-cel; JCARH125)

Anti-BCMA CAR T Cells

Learn More
Phase 3

ozanimod

S1P

Ozanimod is an oral, sphingosine-1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).

 

Learn More

Flip

Phase Post Approval Research

pomalidomide

IMiD? Agent

Pomalidomide is an oral immunomodulatory agent.

Learn More

Flip

romidepsin

( Histone Deacetylase Inhibitor )

Learn More View clinical trials
with this compound
Phase 3, Phase Post Approval Research

romidepsin

Histone Deacetylase Inhibitor

The epigenetic modifier romidepsin is a potent class 1 selective histone deacetylase inhibitor.

Learn More

Flip

thalidomide
Phase Post Approval Research

thalidomide